Weight management pharmacotherapy has advanced considerably in recent years. Medicines developed for type
2 diabetes have demonstrated significant efficacy for weight reduction and are now widely prescribed for this
indication. This overview summarises the clinical rationale for supervised treatment, how these medicines work,
and what patients should expect from a structured weight management pathway.
Why clinical supervision is required
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are prescription-only medicines (POM).
Appropriate use requires a full clinical assessment, as these medicines are contraindicated or require caution in
several patient groups, including those with a personal or family history of medullary thyroid carcinoma,
Multiple Endocrine Neoplasia syndrome type 2, or a history of pancreatitis.
A CQC-regulated, GMC-led clinical pathway will typically include:
● Baseline history, examination, and relevant blood tests
● Assessment of BMI, comorbidities, and current medication
● A titration schedule starting at the lowest effective dose
● Scheduled review appointments to monitor tolerability and response
● Structured nutritional and behavioural support alongside pharmacotherapy
Self-sourcing these medicines outside a regulated pathway removes each of these safeguards and carries a
documented risk of counterfeit or substandard product.
Mechanism of action, in brief Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. The two products differ in licensed dose and indication, not in molecule. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist with a distinct pharmacological profile. Across all three, the shared clinical effect is delayed gastric emptying, increased satiety signalling, and — for GLP-1 agonism specifically — glucose-dependent insulinotropic activity.
What a structured programme should include
● Initial assessment: bloods, BMI, medical history, goal-setting
● An individualised medication plan with a defined titration schedule
● Dietetic input to preserve lean mass during active weight loss
● Follow-up appointments at defined intervals to monitor progress and tolerability
● A maintenance and discontinuation plan agreed in advance with the patient
Managing patient expectations
Weight loss under GLP-1 or dual-agonist therapy is typically gradual, with meaningful results accumulating
over several months of consistent dosing. Rapid or excessive weight loss should prompt clinical review.
Gastrointestinal effects — nausea, constipation, or diarrhoea — are the most commonly reported adverse
effects, particularly during dose escalation, and are usually managed with dose adjustment and dietary guidance
rather than discontinuation.
Discontinuation should always be a planned clinical decision. Evidence indicates that weight regain is common
without a structured maintenance plan, so this should be addressed at the outset of treatment, not only once a
goal weight is reached.
Selecting a provider
Patients should confirm that a prospective clinic is CQC-registered and that prescribing clinicians are GMC-
registered. A responsible provider will never issue a prescription without a documented clinical assessment, and
will be transparent about risk, cost, and the scope of ongoing support included in the programme.
Ready to find out if this is right for you?
Stemax Consult operates CQC-accredited clinical sites in Milton Keynes and Aberdeen, led by GMC-registered
clinicians. To arrange a clinical assessment for weight management treatment, call us today on 01908 032992 to
book a consultation.
This article is provided for general clinical information and does not constitute individual medical advice.
Patients should discuss suitability for treatment with a registered healthcare professional.